Business
BioTrinity Presentation Available Online
BioTrinity Presentation Available Online.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n RNS Number : 5634L\n Sareum Holdings PLC\n 01 May 2020\n \n \n \n \n 1 May 2020\n \n \n Sareum Holdings PLC\n \n \n (\"Sareum\" or the \"Company\")\n \n \n Sareum Presentation at BioTrinity 2020 Available on Company Website\n \n \n Sareum Holdings plc (AIM:SAR)\n , the specialist small molecule drug development business\n , announces that, further to its announcement of 28 April 2020, the Company's virtual presentation, including the video content, given by its CEO, Dr Tim Mitchell, at BioTrinity 2020 (28 April - 1 May 2020) can now be viewed via the Company's website, \n \n www.sareum.com\n \n \n and at\n \n \n bit.ly/3aMVo8Z\n \n .\n \n \n For further information, please contact: \n \n \n Sareum Holdings plc\n \n \n Tim Mitchell, CEO 01223 497 700\n \n \n Strand Hanson Limited (Nominated Adviser)\n \n \n James Dance / Richard Tulloch 020 7409 3494\n \n \n Hybridan LLP (Nominated Broker)\n \n \n Claire Noyce / John Beresford-Peirse 020 3764 2341\n \n \n Citigate Dewe Rogerson (Financial PR)\n \n \n Mark Swallow/ David Dible 020 7638 9571\n \n About Sareum\n Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune disease. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.\n \n Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802). The Company is targeting completion of preclinical development for each molecule in 2020.\n \n The Company's preclinical FLT3+Aurora inhibitor programme targeting haematological cancers is licensed to a China-based specialty pharma company.\n Sareum also has an economic interest in SRA737, a clinical-stage ...